3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
94
Prostatic Neoplasms, Castration-Resistant
10
Neoplasm Metastasis
8
Breast Neoplasms
8
Neoplasms
7
Triple Negative Breast Neoplasms
4
Metastatic Castration-Resistant Prostate Cancer
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Bulbo-Spinal Atrophy, X-Linked
3
Adenocarcinoma
3
mCRPC
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Prostate Adenocarcinoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Bites and Stings
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Interventions
Carboplatin
9
pembrolizumab
7
Pemetrexed
7
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Radiation
4
Nivolumab
4
Bevacizumab
4
Platinum
3
Paclitaxel
3
Mastectomy, Segmental
3
Cisplatin
3
Biopsy
3
fludarabine phosphate
2
durvalumab
2
capmatinib
2
aldesleukin
2
Taxes
2
Radiotherapy, Conformal
2
Radiosurgery
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
Anterior Temporal Lobectomy
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled